{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06297590",
            "orgStudyIdInfo": {
                "id": "18795"
            },
            "secondaryIdInfos": [
                {
                    "id": "J4T-MC-OLAA",
                    "type": "OTHER",
                    "domain": "Eli Lilly and Company"
                },
                {
                    "id": "2024-510604-37-00",
                    "type": "OTHER",
                    "domain": "EU Trial Number"
                },
                {
                    "id": "U1111-1302-6222",
                    "type": "OTHER",
                    "domain": "Universal Trial Number"
                }
            ],
            "organization": {
                "fullName": "Eli Lilly and Company",
                "class": "INDUSTRY"
            },
            "briefTitle": "A First-In-Human Study of LY3954068 in Participants With Early Symptomatic Alzheimer's Disease",
            "officialTitle": "A Single- and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3954068 in Patients With Early Symptomatic Alzheimer's Disease",
            "therapeuticArea": [
                "Neurology"
            ],
            "study": "a-first-in-human-study-of-in-participants-with-early-symptomatic-alzheimer-s-disease"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "NOT_YET_RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-07",
                "type": "ESTIMATED"
            },
            "primaryCompletionDateStruct": {
                "date": "2027-02",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2027-02",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-03-01",
            "studyFirstSubmitQcDate": "2024-03-01",
            "studyFirstPostDateStruct": {
                "date": "2024-03-07",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-23",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-24",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Eli Lilly and Company",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The main purpose of this study is to evaluate the safety of LY3954068 in participants with early symptomatic Alzheimer's Disease (AD). The study will also investigate how much LY3954068 gets into the bloodstream and will test the effects of LY3954068 on markers of AD.\n\nThe study will be comprised of two parts, A and B. Part B is optional, and participants from Part A may also have the opportunity to join an optional bridging period to a separate potential study where participants would receive LY3954068. Each enrolled participant in Part A will receive a single dose of LY3954068 or placebo (no active drug) given into the spinal fluid. If conducted, each participant in Part B would receive 2 doses of either LY3954068 or placebo administered into the spinal fluid.\n\nThe study will last up to approximately 45 weeks for Part A, and, if conducted, 73 weeks for Part B, including the screening period.\n\nIf the optional bridging period is conducted, participants in Part A could be enrolled in the separate potential study for up to approximately 96 weeks, including the screening period."
        },
        "conditionsModule": {
            "conditions": [
                "Alzheimer Disease"
            ],
            "keywords": [
                "Dementia",
                "Brain Diseases",
                "Central Nervous System Diseases",
                "Nervous System Diseases",
                "Tauopathies",
                "Tau",
                "Neurodegenerative Diseases",
                "Neurocognitive Disorders",
                "Mental Disorders",
                "Mild Cognitive Impairment"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "BASIC_SCIENCE",
                "maskingInfo": {
                    "masking": "DOUBLE",
                    "whoMasked": [
                        "PARTICIPANT",
                        "INVESTIGATOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 32,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "LY3954068 (Part A)",
                    "type": "EXPERIMENTAL",
                    "description": "Single ascending dose of LY3954068 administered intrathecally (IT)",
                    "interventionNames": [
                        "Drug: LY3954068",
                        "Drug: Flortaucipir F18"
                    ]
                },
                {
                    "label": "Placebo (Part A)",
                    "type": "PLACEBO_COMPARATOR",
                    "description": "Single ascending dose of placebo administered IT",
                    "interventionNames": [
                        "Drug: Placebo",
                        "Drug: Flortaucipir F18"
                    ]
                },
                {
                    "label": "LY3954068 (Optional Part B)",
                    "type": "EXPERIMENTAL",
                    "description": "Multiple ascending dose of LY3954068 administered IT",
                    "interventionNames": [
                        "Drug: LY3954068",
                        "Drug: Flortaucipir F18"
                    ]
                },
                {
                    "label": "Placebo (Optional Part B)",
                    "type": "PLACEBO_COMPARATOR",
                    "description": "Multiple ascending dose of placebo administered IT",
                    "interventionNames": [
                        "Drug: Placebo",
                        "Drug: Flortaucipir F18"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "LY3954068",
                    "description": "Administered IT",
                    "armGroupLabels": [
                        "LY3954068 (Optional Part B)",
                        "LY3954068 (Part A)"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Placebo",
                    "description": "Administered IT",
                    "armGroupLabels": [
                        "Placebo (Optional Part B)",
                        "Placebo (Part A)"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Flortaucipir F18",
                    "description": "Administered intravenously (IV) prior to Positron Emission Tomography (PET) scan",
                    "armGroupLabels": [
                        "LY3954068 (Optional Part B)",
                        "LY3954068 (Part A)",
                        "Placebo (Optional Part B)",
                        "Placebo (Part A)"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Part A: Number of participants with one or more Adverse Event (s) (AEs), Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) considered by the investigator to be related to study drug administration",
                    "description": "A summary of AEs, TEAEs, SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the reported adverse events module",
                    "timeFrame": "Baseline up to Week 24 and Week 72 (for optional bridging period participants)"
                },
                {
                    "measure": "Part B: Number of participants with one or more Adverse Event (s) (AEs), Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) considered by the investigator to be related to study drug administration",
                    "description": "A summary of AEs, TEAEs, SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the reported adverse events module",
                    "timeFrame": "Baseline up to Week 52"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Part A: Pharmacokinetics (PK): Maximum Observed Concentration (Cmax)",
                    "description": "To evaluate plasma concentration of LY3954068",
                    "timeFrame": "Day 1 up to Week 24"
                },
                {
                    "measure": "Optional Part B: PK: Cmax",
                    "description": "To evaluate plasma concentration of LY3954068",
                    "timeFrame": "Day -1 up to Week 52"
                },
                {
                    "measure": "Part A: PK: Area Under the Concentration Versus Time Curve (AUC)",
                    "description": "To evaluate plasma concentration of LY3954068",
                    "timeFrame": "Day 1 up to Week 24"
                },
                {
                    "measure": "Optional Part B: PK: AUC",
                    "description": "To evaluate plasma concentration of LY3954068",
                    "timeFrame": "Day -1 up to Week 52"
                },
                {
                    "measure": "Part A: PK: Cerebrospinal Fluid (CSF) concentration of LY3954068",
                    "description": "To evaluate CSF concentration of LY3954068",
                    "timeFrame": "Day 3 up to Week 24"
                },
                {
                    "measure": "Optional Part B: PK: CSF concentration of LY3954068",
                    "description": "To evaluate CSF concentration of LY3954068",
                    "timeFrame": "Day 3 up to Week 52"
                },
                {
                    "measure": "Part A: Pharmacodynamics (PD): Change from Baseline of CSF tau",
                    "description": "To evaluate the effect of LY3954068 on CSF tau",
                    "timeFrame": "Baseline up to Week 24"
                },
                {
                    "measure": "Optional Part B: PD: Change from Baseline of CSF tau",
                    "description": "To evaluate the effect of LY3954068 on CSF tau",
                    "timeFrame": "Baseline up to Week 52"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Have a body mass index (BMI) within the range 18 (17 for Japan participants) to 40 kilograms per square meter (kg/m\u00b2), inclusive, at screening.\n* Have gradual and progressive change in memory function for greater than or equal to (\u2265) 6 months as reported by the participant or informant.\n* Have a mini mental state examination (MMSE) score of 18 to 30 at screening.\n* Have a clinical dementia rating (CDR) global score of 0.5 to 1.0, with a memory box score \u2265 0.5 at screening.\n* Meet flortaucipir F18 positron emission tomography (PET) criteria, as defined in the TAUVID\u2122 FDA label (TAUVID\u2122 prescribing information, 2024), demonstrating evidence of tau pathology.\n* Males who agree to follow contraceptive requirements, or women not of childbearing potential (WNOCBP).\n* Participants must have up to 2 study partners who are with contact with the participant at least 10 hours per week and one of whom can attend study appointments.\n\nExclusion Criteria:\n\n* Has current serious or unstable illnesses including cardiovascular, hepatic, renal, gastroenterological, respiratory, endocrinologic, neurologic (other than Alzheimer's Disease), psychiatric, immunologic, or hematologic disease and other conditions that, in the investigator's opinion, could interfere with the analyses in this study; or has a life expectancy of less than (\\<)24 months.\n* Have a sensitivity to flortaucipir F18.\n* Have contraindication to magnetic resonance imaging (MRI), including claustrophobia or the presence of contraindicated metal (ferromagnetic) implants/cardiac pacemaker.\n* Have a current exposure to an amyloid targeted therapy (ATT). Prior exposure to ATTs greater than 1 year from the last dose may be permitted at the discretion of the investigator and in consultation with the sponsor.\n* Have previous exposure to any Investigational Medicinal Product administered intrathecal (IT) or previous exposure to any anti-tau therapy.\n* Have a history of clinically significant back pain, back pathology and/or back injury (for example, degenerative disease, spinal deformity or spinal surgery) that may predispose to complications or technical difficulty with lumbar puncture.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "50 Years",
            "maximumAge": "85 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or",
                    "role": "CONTACT",
                    "phone": "1-317-615-4559",
                    "email": "ClinicalTrials.gov@Lilly.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)",
                    "affiliation": "Eli Lilly and Company",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "K2 Medical Research LLC",
                    "city": "Maitland",
                    "state": "Florida",
                    "zip": "32751",
                    "country": "United States",
                    "contacts": [
                        {
                            "role": "CONTACT",
                            "phone": "407-500-5252"
                        },
                        {
                            "name": "Brandon Lenox",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 28.62778,
                        "lon": -81.36312
                    }
                },
                {
                    "facility": "Charter Research, LLC",
                    "city": "The Villages",
                    "state": "Florida",
                    "zip": "32162",
                    "country": "United States",
                    "contacts": [
                        {
                            "role": "CONTACT",
                            "phone": "352-775-1000"
                        },
                        {
                            "name": "Jeffrey Norton",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 28.93408,
                        "lon": -81.95994
                    }
                },
                {
                    "facility": "CenExel iResearch, LLC (CenExel iRA)",
                    "city": "Decatur",
                    "state": "Georgia",
                    "zip": "30030",
                    "country": "United States",
                    "contacts": [
                        {
                            "role": "CONTACT",
                            "phone": "404-537-1281"
                        },
                        {
                            "name": "Kimball Johnson",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 33.77483,
                        "lon": -84.29631
                    }
                },
                {
                    "facility": "Indiana University School of Medicine",
                    "city": "Indianapolis",
                    "state": "Indiana",
                    "zip": "46202",
                    "country": "United States",
                    "contacts": [
                        {
                            "role": "CONTACT",
                            "phone": "317-963-7505"
                        },
                        {
                            "name": "Jared Brosch",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 39.76838,
                        "lon": -86.15804
                    }
                },
                {
                    "facility": "Massachusetts General Hospital (MGH)",
                    "city": "Charlestown",
                    "state": "Massachusetts",
                    "zip": "02129",
                    "country": "United States",
                    "contacts": [
                        {
                            "role": "CONTACT",
                            "phone": "617-643-5607"
                        },
                        {
                            "name": "Steven Arnold",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 42.37787,
                        "lon": -71.062
                    }
                },
                {
                    "facility": "CenExel AMRI",
                    "city": "Toms River",
                    "state": "New Jersey",
                    "zip": "08755",
                    "country": "United States",
                    "contacts": [
                        {
                            "role": "CONTACT",
                            "phone": "732-341-9500"
                        },
                        {
                            "name": "Sanjiv Sharma",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 39.95373,
                        "lon": -74.19792
                    }
                },
                {
                    "facility": "Duke University",
                    "city": "Durham",
                    "state": "North Carolina",
                    "zip": "27710",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Shruti Raja",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 35.99403,
                        "lon": -78.89862
                    }
                },
                {
                    "facility": "Medical College of Wisconsin",
                    "city": "Milwaukee",
                    "state": "Wisconsin",
                    "zip": "53226",
                    "country": "United States",
                    "contacts": [
                        {
                            "role": "CONTACT",
                            "phone": "414-955-0650"
                        },
                        {
                            "name": "Malgorzata Franczak",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 43.0389,
                        "lon": -87.90647
                    }
                },
                {
                    "facility": "The University of Tokyo Hospital",
                    "city": "Bunkyo-ku",
                    "state": "Tokyo",
                    "zip": "113-8655",
                    "country": "Japan",
                    "contacts": [
                        {
                            "role": "CONTACT",
                            "phone": "+81-33-815-5411"
                        },
                        {
                            "name": "Takeshi Iwatsubo",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 35.37517,
                        "lon": 139.92991
                    }
                },
                {
                    "facility": "National Hospital for Neurology and Neurosurgery (UCLH)",
                    "city": "London",
                    "zip": "WC1N 3BG",
                    "country": "United Kingdom",
                    "contacts": [
                        {
                            "role": "CONTACT",
                            "phone": "0203 448 3011"
                        },
                        {
                            "name": "Catherine Mummery",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 51.50853,
                        "lon": -0.12574
                    }
                },
                {
                    "facility": "Royal Hallamshire Hospital",
                    "city": "Sheffield",
                    "zip": "S10 2JF",
                    "country": "United Kingdom",
                    "contacts": [
                        {
                            "name": "Daniel Blackburn",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 53.38297,
                        "lon": -1.4659
                    }
                },
                {
                    "facility": "University Hospital Southampton",
                    "city": "Southampton",
                    "zip": "SO16 6YD",
                    "country": "United Kingdom",
                    "contacts": [
                        {
                            "name": "Christopher Kipps",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 50.90395,
                        "lon": -1.40428
                    }
                }
            ]
        },
        "referencesModule": {
            "seeAlsoLinks": [
                {
                    "label": "A First-In-Human Study of LY3954068 in Participants With Early Symptomatic Alzheimer's Disease",
                    "url": "https://trials.lilly.com/en-US/trial/466315"
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000000544",
                    "term": "Alzheimer Disease"
                }
            ],
            "ancestors": [
                {
                    "id": "D000003704",
                    "term": "Dementia"
                },
                {
                    "id": "D000001927",
                    "term": "Brain Diseases"
                },
                {
                    "id": "D000002493",
                    "term": "Central Nervous System Diseases"
                },
                {
                    "id": "D000009422",
                    "term": "Nervous System Diseases"
                },
                {
                    "id": "D000024801",
                    "term": "Tauopathies"
                },
                {
                    "id": "D000019636",
                    "term": "Neurodegenerative Diseases"
                },
                {
                    "id": "D000019965",
                    "term": "Neurocognitive Disorders"
                },
                {
                    "id": "D000001523",
                    "term": "Mental Disorders"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M3885",
                    "name": "Alzheimer Disease",
                    "asFound": "Alzheimer's Disease",
                    "relevance": "HIGH"
                },
                {
                    "id": "M21558",
                    "name": "Neurodegenerative Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M29705",
                    "name": "Cognitive Dysfunction",
                    "relevance": "LOW"
                },
                {
                    "id": "M4815",
                    "name": "Mental Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M6904",
                    "name": "Dementia",
                    "relevance": "LOW"
                },
                {
                    "id": "M21836",
                    "name": "Neurocognitive Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M5204",
                    "name": "Brain Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M14473",
                    "name": "Psychotic Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M5742",
                    "name": "Central Nervous System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M23002",
                    "name": "Tauopathies",
                    "relevance": "LOW"
                },
                {
                    "id": "T2192",
                    "name": "Familial Alzheimer Disease",
                    "asFound": "Alzheimer's Disease",
                    "relevance": "HIGH"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC10",
                    "name": "Nervous System Diseases"
                },
                {
                    "abbrev": "BXM",
                    "name": "Behaviors and Mental Disorders"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        }
    },
    "hasResults": false
}